Cyclosporine Formulation and Kaposi’s Sarcoma after Renal Transplantation
Article 2005 en
Authors
DC
Dario Cattaneo
EG
Eliana Gotti
NP
Norberto Perico
Abstract
1 min read
In recipients of kidney transplant CsA Neoral increases the risk of KS as compared to the Sandimmune formulation, possibly due to enhanced drug bioavailability and ultimately patients daily CsA exposure.
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.